Karus Therapeutics Appoints Penelope Ward as CMO
News Nov 12, 2013
Karus Therapeutics has announced that Penelope Ward has joined the Company in the role of Chief Medical Officer.
Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.
Dr Ward, who took up her new position in October, is an experienced pharmaceutical physician with previous senior management roles at Pharmacia and Upjohn (Pfizer), UCB and Roche, and was previously Chief Medical Officer of Novimmune SA.
Her expertise in designing and implementing clinical development strategies will be important for the role at Karus where she will take responsibility for driving the Company’s HDAC6 and PI3K inhibitor programmes through early human efficacy trials in inflammation and cancer.
In addition, Dr Ward brings with her broad capabilities in commercial licensing negotiations, having previously supported deals for novel research targets to full development candidates.
Along with a solid track record in obtaining regulatory approval, Dr Ward is well placed to assist the Company in future strategic decision making.
Commenting on Dr Ward’s appointment, Dr Simon Kerry, Chief Executive of Karus, said: “With the wealth of expertise that Penny brings to the position, we are confident she will be an asset to the team and look forward to working together to further develop and strengthen our proprietary programmes to treat inflammation and cancer.”
Dr Ward, Chief Medical Officer, added: “Karus is at a very exciting stage in its development, being well funded by supportive investors and with a great team. I look forward to working with the Board, management and scientists to progress the Company’s assets and realize the potential of its technology.”
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function. In people who have glioblastoma, the deadliest form of brain cancer, this fluid has a much higher pressure, causing it to move fast and forcing cancer cells to spread. Researchers may have found a solution to stopping this inevitable cancer cell spread.READ MORE
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019